LIAN
Price:
$0.319
Market Cap:
$34.47M
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for u...[Read more]
Industry
Biotechnology
IPO Date
2021-11-01
Stock Exchange
NASDAQ
Ticker
LIAN
According to LianBio’s latest financial reports and current stock price. The company's current PE Ratio is -0.39. This represents a change of -82.89% compared to the average of -2.27 of the last 4 quarters.
The mean historical PE Ratio of LianBio over the last ten years is -18.47. The current -0.39 PE Ratio has changed 110.59% with respect to the historical average. Over the past ten years (40 quarters), LIAN's PE Ratio was at its highest in in the September 2020 quarter at -0.29. The PE Ratio was at its lowest in in the December 2020 quarter at -28.30.
Average
-18.47
Median
-5.97
Minimum
-60.88
Maximum
-1.08
Discovering the peaks and valleys of LianBio PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 48.69%
Maximum Annual PE Ratio = -1.08
Minimum Annual Increase = -89.55%
Minimum Annual PE Ratio = -60.88
Year | PE Ratio | Change |
---|---|---|
2022 | -1.60 | 48.69% |
2021 | -1.08 | -89.55% |
2020 | -10.33 | -83.03% |
The current PE Ratio of LianBio (LIAN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-4.34
5-year avg
-18.47
10-year avg
-18.47
LianBio’s PE Ratio is greater than Sensei Biotherapeutics, Inc. (-0.52), greater than NextCure, Inc. (-0.65), greater than Nuvation Bio Inc. (-1.34), less than Graphite Bio, Inc. (-0.13), greater than Merrimack Pharmaceuticals, Inc. (-8.92), greater than Inozyme Pharma, Inc. (-3.48), greater than Day One Biopharmaceuticals, Inc. (-7.39), greater than Terns Pharmaceuticals, Inc. (-6.06), greater than Eledon Pharmaceuticals, Inc. (-1.43), greater than HOOKIPA Pharma Inc. (-1.22), less than Fennec Pharmaceuticals Inc. (54.24), greater than Larimar Therapeutics, Inc. (-8.80), greater than Verrica Pharmaceuticals Inc. (-1.02), less than Homology Medicines, Inc. (-0.01), greater than Neoleukin Therapeutics, Inc. (-0.98), greater than Instil Bio, Inc. (-0.78), greater than Achilles Therapeutics plc (-0.45), greater than Assembly Biosciences, Inc. (-2.10), greater than Acumen Pharmaceuticals, Inc. (-2.06),
Company | PE Ratio | Market cap |
---|---|---|
-0.52 | $15.32M | |
-0.65 | $39.73M | |
-1.34 | $692.60M | |
-0.13 | $185.19M | |
-8.92 | $223.97M | |
-3.48 | $312.42M | |
-7.39 | $1.25B | |
-6.06 | $549.60M | |
-1.43 | $100.73M | |
-1.22 | $159.50M | |
54.24 | $144.76M | |
-8.80 | $513.64M | |
-1.02 | $81.50M | |
-0.01 | $3.02M | |
-0.98 | $8.20M | |
-0.78 | $92.68M | |
-0.45 | $29.58M | |
-2.10 | $107.81M | |
-2.06 | $133.38M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like LianBio using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like LianBio or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is LianBio's PE Ratio?
How is the PE Ratio calculated for LianBio (LIAN)?
What is the highest PE Ratio for LianBio (LIAN)?
What is the 3-year average PE Ratio for LianBio (LIAN)?
What is the 5-year average PE Ratio for LianBio (LIAN)?
How does the current PE Ratio for LianBio (LIAN) compare to its historical average?